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In addition to the antihyperglycemic effects, metformin has shown to inhibit glycation of 
proteins, protecting their structure and function in diabetes-associated complications. Formation 
of nonenzymatic advanced glycation end products was studied in the presence of antidiabetic 
agent metformin and its structural analogs: phenformin, buformin, guanidinobutyric acid, and 
aminoguanidine. MGO was used as the glycating agent while aminoguanidine was used as the 
known antiglycation agent. The rate and extent of fluorescence generated upon formation of the 
in vitro cross-linked BSA by MGO was studied using the excitation wavelength of 330 nm. The 
fluorescence emission spectra of cross-linked BSA gave maximum values at 410 – 430 nm, 
regardless of the inhibitors used. The fluorescence generation was measured at 410 nm at 30°C 
over 96 hours at two concentrations of metformin and its analogs. At 10 mM MGO, no inhibition 
was exhibited and metformin and its structural analogs seemed to promote glycation. At 30 mM 
MGO, metformin (81%) and phenformin (93%) showed reduced glycation at 0.8 mM. At 30 mM 
MGO, buformin (51%), guanidinobutyric acid (69%), and metformin (94%) showed reduced 
glycation at 2.0 mM. At 100 mM, phenformin (86%) and metformin (84%) showed reduced 
glycation at 0.8 mM. At 100 mM, metformin (85%) was found to be the only drug to reduce 
glycation at 2.0 mM.  Neither metformin nor its structural analogs proved to be as effective as 
aminoguanidine. The molecular weights of the cross-linked products determined by SDS PAGE 
indicated the formation of intramolecular cross-linked proteins in the presence of metformin and 
its structural analogs. SDS PAGE also confirmed that metformin and its analogs studied here 
were not potent antiglycation agents in vitro.     
INTRODUCTION 
Type 2 Diabetes Mellitus (T2D) is the most common form of diabetes, totaling 90% to 95% of 
all cases of diabetes. It is characterized by high blood glucose levels that result from a decrease 
in glucose uptake in muscle and adipose tissue, as well as an increase in hepatic 
gluconeogenesis.1 Metformin is a common medication used in the oral treatment of T2D.  It is 
shown to suppress hepatic gluconeogenesis by non-competitively inhibiting mitochondrial 
glycerophosphate dehydrogenase.2 Metformin has the following structural analogs: phenformin, 
buformin, aminoguanidine and guanidinobutyric acid.  
 
Figure 1: Metformin 
(3-carbamimidoyl-1,1-dimethylbiguanide) 
 
Figure 2: Phenformin 
(N-(2-Phenylethyl) imidodicarbonimidic diamide) 
 





Figure 4: Aminoguanidine 
(N-Butylimidodicarbonimidic diamide) 
 
Figure 5: Guanidinobutyric Acid 
(4-Carbamimidamidobutanoic acid) 
Hyperglycemia resulting from diabetes can lead to the non-enzymatic glycation of proteins.3 
Glycation is a spontaneous process involving amino-carbonyl reactions between reducing sugars 
and proteins. This causes chemical modification of biomolecules that compromises function and 
can lead to the formation of reactive oxidative species. Metformin is thought to be an inhibitor of 
glycation through a mechanism of trapping methylglyoxal (MGO) and other dicarbonyls during 
the glycation process.4 The mechanism of inhibition by other inhibitors is thought to be either 
chelation of metals or indirect inhibition of formation of reactive carbonyl compounds. MGO is 
able to cross-link lysine residues of proteins, which leads to conformational and functional 
changes of the protein involved.  
 
Figure 6: Lysine Residues cross-linked with methylglyoxal5 
Accumulation of these advanced glycation end products can cause various medical 
complications including: atherosclerosis, nephropathy, neuropathy and cataracts.5 Inhibition of 
glycation has an inverse relationship with the concentration of a known inhibitor. This has been 
observed in studies involving bovine serum albumin (BSA) and diethylenetriaminepenta-acetic 
acid, a known agent which reduces the covalent attachment of glucose to BSA in two different 
modes.3,6 In our study, in vitro glycation of BSA was studied at varying concentrations of MGO 
in order to examine the effects of metformin and its analogs on molecular cross-linking.  
MATERIALS AND METHODS 
All materials were obtained from Sigma Aldrich and BioRad. Samples of varying 
concentrations of filtered-sterilized MGO, BSA, antidiabetic agent, buffer, and water were 
prepared in 100 mM phosphate buffer with a pH of 7.4, and added the BSA and the MGO last to 
prevent the formation of unwanted aggregates. Using the microplate reader and sterile 
equipment, the amount of glycation on BSA was measured fluorimetrically at 30 °C. The 
excitation was 330 nm and an emission spectrum of cross-linked BSA was found to have a 
maximum emission at 410-430 nm. This wavelength was used to measure the fluorescence 
intensity of the solutions. The samples were ran as triplicates or quadruplicates, and averaged. 
Standard addition of the BSA and MGO was completed to correct for emitted fluorescence and 
graphed as a function of time. The control group (BSA+MGO) was normalized to 100%, and the 
percent glycation of BSA in the presence of metformin analogs were respectively determined. 
SDS and Native PAGE samples were each prepared for BSA and cross-linked BSA. The Native 
PAGE samples consisted of 125 µL PAGE buffer, 105 µL 100 mM phosphate buffer, and 20 µL 
sample. The prepared native samples were then added to the gel and the apparatus was set to 200 
V and was run until the tracking dye was about 1cm away from the bottom of the gel. The gels 
were rinsed with water once for 5 minutes and then placed in the dye until the bands were 
visible. SDS PAGE samples consisted of 125 µL PAGE buffer, 400 µL 100 mM phosphate 
buffer, and 20 µL sample. Molecular docking simulations were done to test the binding affinity 
of metformin analogs to BSA using DockingServer.  
RESULTS 
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Graph 4: Percent Glycation at 100 mM MGO and 2 mM Metformin Analog 
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Graph 6: Percent Glycation at 30 mM MGO and 0.8 mM Metformin Analog 
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Graph 8: Percent Glycation at 30 mM MGO and 2 mM Metformin Analog 
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Graph 10: Percent Glycation at 10 mM MGO and 0.8 mM Drug 
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Graph 12: Percent Glycation at 10 mM MGO and 2 mM Drug 
 
Figure 7: SDS PAGE of 100 mM MGO with varying concentrations of Metformin  
* Molecular Ladder 
1 2 3 4 5 6 7 8 9 10 
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DISCUSSION 
The purpose of this experiment was to observe the effect of metformin and its structural 
analogs on the in-vitro glycation of BSA. The glycation reactions were measured using a 
microplate fluorimeter with excitation at 330 nm and emission at 410 nm with solution 
conditions of 10 mM, 30 mM, and 100 mM MGO, as well as, 0.8 mM or 2 mM concentrations of 
the metformin analogs. At 10 mM MGO, no inhibition was exhibited and the metformin analogs 
appeared to promote glycation. At 30 mM MGO and 0.8 mM drugs, metformin (81% glycation 
compared to the control) and Phenformin (93%) slightly inhibited glycation while the known 
inhibitor, aminoguanidine showed 48% glycation. At 30 mM MGO and 2 mM drugs, buformin 
(51%), guanidinobutyric acid (69%), and metformin (94%) showed reduced glycation. At 100 
mM and 0.8 mM drugs, phenformin (86%) and metformin (84%) showed reduced glycation 
while aminoguanidine showed 49% glycation. At 100 mM and 2 mM drugs, metformin (85%) 
was found to be the only drug to reduce glycation. The 30 mM and 100 mM MGO 
concentrations had a relative standard deviation of 10-15% and the 10 mM had ranging relative 
standard deviations from 10-50%. In addition, SDS-PAGE gels were completed to determine 
whether there were more intermolecular or intramolecular cross-linking. Due to the fact that 
there were no molecular weights that showed to be double the size, it is known that the cross-
linking is intramolecular. The molecular docking simulations indicated that there was no 
significant interaction between BSA and the metformin analogs. This was shown in the binding 
affinities of BSA and metformin (-0.2 kcal/mol), phenformin (+0.53 kcal/mol), and buformin 
(+0.59 kcal/mol). 
CONCLUSION  
In conclusion, aminoguanidine, which is a known inhibitor of glycation, showed the most 
inhibition of glycation. The tested metformin and its analogs did not significantly inhibit 
glycation when compared to aminoguanidine. When comparing the 0.8 mM and the 2 mM 
concentrations, the 0.8 mM was found to have slightly greater inhibition over 2 mM. At 10 mM 
MGO, the metformin analogs showed increased glycation compared to the BSA control for both 
concentrations of MGO. The SDS PAGE supported the kinetic data by showing no significant 
differences in molecular weights of the glycated BSA in the presence or absence of metformin. 
Docking simulations showed that there was no significant interaction between BSA and the 
metformin analogs. In the future, we plan to examine the 13C NMR to observe any interactions 
between metformin and its analogs with MGO. Since aminoguanidine is known to trap MGO by 
reacting with its two carbonyl groups, it is thought that metformin and its structural analogs 
would interact similarly due to their analogous functional group.  
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